For an emerging US-based biopharma company, there are many “pathways” to maximizing value in ex-US markets, and the best one for a given situation isn’t always obvious.
Questions abound. Why should we expand beyond the US market? What are the potential pathways? How does the company decide between them?
Attendees to this webinar will hear from a panel of seasoned biopharma executives who have successfully grappled with these same questions. In particular, attendees will:
- Learn about the major pathways to value companies have taken over the past few years (i.e., does “going it alone” generate more value than partnering?).
- Explore a framework for assessing the options and making critical strategic decisions on your own journey.
- Discuss case studies from companies that have taken different pathways to value.